{"classes":[{"title":"Any AEs"},{"title":"Any SAEs"}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A SAE is defined as any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect and other important medical events judged by the investigator that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention. This analysis was planned but not performed for Part C as the study was terminated early during Part B.","groups":[{"description":"Participants were planned to receive repeat dosing of GSK3039294 at the predicted optimal clinical dose determined from Part B for a total of 21 days.","id":"OG000","title":"Part C: GSK3039294"}],"populationDescription":"Safety Population. Data was not collected as study was terminated due to safety reasons during conduct of Part B (end of Cohort 3) whereas Part C was not initiated.","reportingStatus":"POSTED","timeFrame":"Up to Day 63","title":"Part C: Number of Participants With AEs and SAEs","type":"PRIMARY"}